News

Patent-Thickets in the News

August 3, 2020

Recently the practice of establishing so called patent-thickets for biologic products has been questioned as a potentially abusive way of preventing biosimilar competition.  In June 2020, the Honorable Judge Manish S. Shah in the United States District Court for the Northern District of Illinois Eastern Division issued a Memorandum Opinion and Order dismissing a class...   Read More

Tags:  Featured , Gleason IP

Pricing in the Pharmaceutical Industry

August 3, 2020

Drug pricing in the United States has been a political hot topic in recent years.  On July 24, 2020, President Trump signed four executive orders on lowering drug prices.  This multifaceted issue has numerous stakeholders with far reaching financial impacts. The backdrop of the current global pandemic creates additional complications for pharmaceutical companies seeking to...   Read More

Tags:  Featured , Gleason IP

Remote Depositions in Response to COVID-19

August 3, 2020

The COVID-19 pandemic and related stay-at-home directives have led to an increase in remote depositions.  Historically, attorneys have been reluctant to conduct remote depositions, but there can be certain advantages to be gained from their adoption.  On several occasions, Gleason Managing Directors have been deposed virtually and are providing insight for consideration to aid in...   Read More

Tags:  Featured , Gleason IP

Gleason IP Testimony Supports Client’s Successful Case

August 3, 2020

Gleason IP provided expert testimony on behalf of Teva Pharmaceuticals to establish that the asserted patent claims allegedly covering Adapt Pharma’s opioid overdose drug were invalid due to obviousness, and that the marketplace performance of Narcan® was attributable to features already known in the prior art, among other extrinsic factors unrelated to the Patents-in-Suit. Engagement In...   Read More

Tags:  Featured , Gleason IP

COVID-19 & Insurance Issues

May 27, 2020

The stay-at-home policies ordering the closure of “nonessential” businesses have wreaked havoc on companies large and small. These restrictions have brought countless businesses to an abrupt halt, and many owners are looking for solutions to recover or at least partially mitigate their losses. Many commercial insurance policies offer business income and extra expense coverage (business...   Read More

Tags:  Gleason Experts

What’s At Risk When Invoking A Force Majeure Clause?

May 27, 2020

Beginning April 1, 2020, Governor Tom Wolf issued a statewide stay-at-home policy for Pennsylvania in an effort to slow the spread of the COVID-19 illness. As a result, many businesses have been forced to cease operations, making it difficult or impossible to uphold their agreements. Governor Wolf’s issuance of a statewide stay-at home policy and...   Read More

Tags:  Gleason Experts

Combating New Opportunities for Corporate Fraud During COVID-19 Outbreak

April 14, 2020

As the term “social distancing” has burst into our daily vocabulary, we are in a new territory of conducting daily business through remote working situations. While this taught us new lessons in creative adaptation, it has also created fresh opportunities for corporate fraud. Protecting yourself, your company, and your employees from these new fraud threats...   Read More

Tags:  Gleason Experts

Remote Data Attacks—Heightened Awareness During COVID-19 Outbreak

April 14, 2020

Disasters have a tendency to bring out the best and worst in people. Sadly, serial fraudsters view events such as the COVID-19 pandemic as the perfect opportunity to strike. They are keenly aware that potential victims and typical watchdogs are likely distracted, stressed and overwhelmed. Unfortunately, fraudsters are well experienced in using fear and panic...   Read More

Tags:  Gleason Experts

Valuation Services and COVID-19

April 8, 2020

The COVID-19 pandemic and the resulting slow down or temporary cessation of many businesses has triggered a massive sell-off in equities, as investors have cut projections and raised equity risk profiles for publicly traded investments in this time of uncertainty.  The sudden decline in equity values provides both challenges and opportunities for business owners and...   Read More

Tags:  Gleason Experts , Uncategorized

COVID-19, Economic Slowdown and the impact on Valuation

April 8, 2020

As uncertainty surrounding the timeline and ability to manage the spread of COVID-19 grows, so does the complexity of managing and valuing businesses.  Social distancing and the reduction or elimination of “non-essential” activity has profoundly disrupted or even closed businesses and supply chains across the United States and globe.  There are a number of environmental...   Read More

Tags:  Gleason Experts

Economic Stimulus Legislation and the Valuation of Privately Held Businesses

April 8, 2020

In response to the substantial economic disruption caused by the COVID-19 pandemic and the associated business shutdowns, the U.S. enacted a series of stimulus measures in late March, including the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the largest stimulus bill in U.S. history.  Among other measures, the CARES Act: Provides funding to various...   Read More

Tags:  Gleason Experts , Uncategorized

William Krieger William Krieger

Krieger Selected to Serve as Subchapter V Trustee

March 23, 2020

Gleason Experts is pleased to announce that William Krieger, a Vice President, Managing Director and shareholder at Gleason has been selected to serve as a Subchapter V Trustee for the Western District of Pennsylvania. Mr. Krieger currently leads Gleason Experts’ bankruptcy and financial reorganization practice area. In 2019, the United States Government enacted the Small...   Read More

Tags:  Gleason Experts

Gleason: Certainty of Service in Uncertain Times

March 23, 2020

The health and well-being of our employees, clients, colleagues and community is our top priority. With the on-going COVID-19 outbreak, we have shifted the GLEASON team to a remote work status. Rest assured, we are still fully operational and remain committed to delivering the same level of quality service our clients have come to know...   Read More

Tags:  Uncategorized

Gleason CLE Event – Opioid Litigation: Extraordinary Justice in Extraordinary Times

October 22, 2019

November 12, 2019 Fairmont Hotel  |  501 Market Street, Pittsburgh, PA 15222 5:00 p.m. Registration | 5:30 p.m. Presentation & Discussion  |  6:30 p.m. Networking Reception x Opioid Litigation:  Extraordinary Justice in Extraordinary Times "Ordinarily, the resolution of a social epidemic should be the responsibility of our other two branches of government, but these are...   Read More

Tags:  Gleason Experts , Uncategorized

Spring Continuing Legal Education Series

April 11, 2019

Fairmont Hotel  |  501 Market Street, Pittsburgh, PA 15222 April 10, 12:00-1:00 pm   |   May 7, 7:30-8:30 am   |   June 5, 7:30-8:30 am Gleason is pleased to present a series of continuing legal education sessions at the Fairmont Hotel in downtown Pittsburgh.  Each of these sessions will cover different topics, which are detailed below.  Please feel...   Read More

Tags:  Gleason Experts , Gleason IP , Gleason Trust

Gleason provides expert valuation services to the Children’s Museum of Pittsburgh

September 28, 2018

The Children’s Museum of Pittsburgh is nearing the end of its “Museumlab” expansion into a former North Side library.   The Museumlab, which will also share space with a charter school, will feature three exhibits: MakeLab, TechLab, and StudioLab.  Gleason Experts provided valuation services to the Children’s Museum of Pittsburgh in connection with New Markets Tax...   Read More

Tags:  Gleason Experts

Mid-Year Market Update: July 2018

July 18, 2018

Market Review and Outlook The M&A market had a huge first half of 2018, with total announced deal value reaching a record of $2.5 trillion - a 61% increase over the first half of 2017.  While overall value is up this year, deal volume slowed by nearly 4% from the same period in 2017.  This drop continues...   Read More

Tags:  Gleason Advisors , Uncategorized

Gleason serves as Financial Advisor in Chapter 11 Bankruptcy of Geo. V. Hamilton, Inc.

May 31, 2018

On March 30, 2018, McKees Rocks-based Geo. V. Hamilton, Inc., a commercial and industrial insulation and distribution contractor, announced that it had exited Chapter 11 bankruptcy under a confirmed plan of reorganization.  Gleason Experts acted as a financial consultant to the Future Claimants’ Representative and the Official Committee of Asbestos Personal Injury Claimants.  As part...   Read More

Tags:  Gleason Experts

2017 Year-End Financial Market Review

January 8, 2018

Optimistic Investors Cheered 2017 Across the Globe, Tax Reform Sets the Stage for Strong Economic Growth in 2018  [SEE FULL REPORT...] While it seems like a lot happened in 2017, in retrospect we struggled to find any one event that defined the year... that is until Tax Reform passed.  The Trump Presidency had its inaugural...   Read More

Tags:  Gleason Advisors

M&A Market Update

June 20, 2017

The Middle Market Environment: Mergers & Acquisition activity in the middle market has remained incredibly high relative to historical levels.  However, the market has retracted from peak levels over the last two years, with the total number of transactions decreasing 3.1% and 12.8% in ’15 & ’16, respectively.  The 1st quarter 2017 was down 8.2%...   Read More

Tags:  Gleason Advisors

Trends in ADR and the Role of Financial Experts

January 1, 2017

The U.S. District Court for the Western District of Pennsylvania implemented Local Rule 16.2 in 2007, which requires parties involved in nearly all civil actions to agree upon some form of Alternative Dispute Resolution (ADR) during the litigation process. During the 18-month pilot period that tested Local Rule 16.2, the court found that 51% of...   Read More

Tags:  Gleason Experts

Early Damages Assessment in Data-Intensive Commercial Disputes

January 1, 2017

In the initial phases of litigation, the focus is placed on legal strategy: the analysis of the facts, the development of legal theories, and the research of case law. More practically, the legal team must also weigh the potential damages to be defended/recovered against the legal fees and related costs that will be expended. However,...   Read More

Tags:  Gleason Experts

Alternative Dispute Resolution and the Role of the Financial Expert

January 1, 2017

Alternative Dispute Resolution, or ADR, has the potential to provide parties with an effective means of settling disputes without litigation. As the structure of ADR continues to evolve, so does the role of the financial expert within ADR processes. By involving a financial expert at the early stages of a dispute, it may be possible...   Read More

Tags:  Gleason Experts

Navigating Patent Litigation Changes: Update on the America Invents Act

January 1, 2017

In Issue 3 of IP Insights, we discussed the Inter Partes Review (IPR) process at the United States Patent and Trademark Office (USPTO) since the Leahy-Smith America Invents Act (AIA) was signed into law. The AIA was approved as part of an effort to improve the quality of the patents issued by the USPTO, to...   Read More

Tags:  Gleason IP

Increased Attention on Pharmaceutical Prices

January 1, 2017

As healthcare costs continue to rise, more and more people have entered the debate over escalating drug prices. One situation that has captured the attention of many involves the drug Daraprim®. Daraprim® (pyrimethamine) is used to treat toxoplasmosis in patients with weak immune systems, such as HIV patients.1 Although Daraprim® has been around for over...   Read More

Tags:  Gleason IP

Gleason IP Helps Clients Win Patent Infringement Case

January 1, 2017

Engagement In a pharmaceutical patent infringement matter, Ivan Hofmann and the team at Gleason IP analyzed various issues and provided expert opinions and testimony concerning objective indicia of nonobviousness related to a patent that allegedly covered a lyophilized formulation of the injectable cancer drug bortezomib (marketed as Velcade®). Specifically, Gleason IP analyzed commercial success as...   Read More

Tags:  Gleason IP